Eton Pharmaceuticals welcomes Jenn Adams to its Board of Directors

– USA, IL –  Eton Pharmaceuticals, Inc (NASDAQ: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Jenn Adams to its board of directors effective March 17, 2021.

Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry.

“We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said CEO, Sean Brynjelsen.

Ms. Adams replaces Mark Baum, who stepped down from the board effective March 17 to devote more time to Harrow Health Inc., where he serves as CEO.

“We are grateful for Mark’s service and valuable contributions. His vision helped to create Eton and his service was instrumental in growing the company to where it is today,” said Sean Brynjelsen.

About Jenn Adams

Her experience includes leading and growing both Fortune 500 public and private equity-backed companies. She currently serves as CEO of August Bioservices, a leading provider of research, development, and manufacturing services to pharmaceutical and biotechnology companies. Before joining August Bioservices, she served as SVP & President, Clinical Product Solutions Business Unit of AmerisourceBergen.

Ms. Adams spent her early career at Baxter Healthcare, serving in leadership roles in its Medication Delivery and Fenwal businesses. Ms. Adams also serves as a Senior Advisor to Oak HC/FT, a venture growth-equity fund investing in healthcare information and services. Ms. Adams serves on the nonprofit Board of LifeScience Tennessee

She holds an MBA from the Northwestern University’s J.L. Kellogg Graduate School of Management.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI SPRINKLE, Biorphen, and Alaway Preservative Free, and has six additional products that have been submitted to the FDA.

For more information: https://etonpharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team